TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Applied Therapeutics ( (APLT) ) is now available.
On November 20, 2025, Applied Therapeutics announced a strategic review to explore alternatives like mergers or partnerships to maximize shareholder value. As part of this process, the company plans to reduce its workforce by 46% by the end of December 2025, aiming to conserve cash and maintain its commitment to developing treatments for rare diseases.
The most recent analyst rating on (APLT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.
Spark’s Take on APLT Stock
According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.
Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.
To see Spark’s full report on APLT stock, click here.
More about Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare diseases. Its lead product, govorestat, is aimed at treating central nervous system rare metabolic diseases such as Classic Galactosemia and Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency.
Average Trading Volume: 11,972,076
Technical Sentiment Signal: Sell
Current Market Cap: $41.13M
Find detailed analytics on APLT stock on TipRanks’ Stock Analysis page.